Targeting a specific protein to treat a type of blood cancer
Targeting FLT3 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
['FUNDING_R01'] · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · NIH-10894216
This study is testing a new treatment for acute myeloid leukemia (AML) using specially designed immune cells that can find and fight cancer cells with a specific protein, aiming to improve survival for patients like you.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE (nih funded) |
| Locations | 1 site (DUARTE, UNITED STATES) |
| Trial ID | NIH-10894216 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a new treatment for acute myeloid leukemia (AML) by using engineered T cells that target the FLT3 protein, which is often found in AML cells. The approach involves creating a chimeric antigen receptor (CAR) that can recognize and attack these cancer cells. The researchers have shown promising results in laboratory models, where these CAR T cells improved survival rates in mice with AML. Additionally, they are exploring the use of natural killer (NK) cells that have been modified to target FLT3, potentially offering another effective treatment option.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with relapsed or refractory acute myeloid leukemia who express the FLT3 protein.
Not a fit: Patients with acute myeloid leukemia who do not express the FLT3 protein may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new and effective treatment option for patients with relapsed or refractory acute myeloid leukemia.
How similar studies have performed: Other research has shown promising results with CAR T cell therapies in treating various blood cancers, although similar successes in AML are still being explored.
Where this research is happening
DUARTE, UNITED STATES
- BECKMAN RESEARCH INSTITUTE/CITY OF HOPE — DUARTE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CALIGIURI, MICHAEL A — BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
- Study coordinator: CALIGIURI, MICHAEL A
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.